系统生物学
肾脏疾病
医学
分子医学
生物
疾病
计算生物学
细胞周期
模拟生物系统
生物信息学
癌症
肾癌
重症监护医学
梅德林
癌基因
医疗保健系统
人体生理学
细胞
慢性病
人类遗传学
系统医学
肾
作者
Jinyi Hou,Yaotan Li,Shijia Lin,Qingqing Liu,Huijuan Zheng,W Liu,Yuxing Wang,Liang Peng,Zi Wang
标识
DOI:10.3892/ijmm.2026.5937
摘要
Chronic kidney disease (CKD) is traditionally studied through an organ‑centric paradigm, despite its frequent coexistence with intestinal dysbiosis and metabolic dysfunction‑associated steatotic liver disease, which confers a 38% increased CKD risk. Multi‑organ crosstalk along the gut‑liver‑kidney axis remains inadequately addressed in current guidelines. The present study aimed to establish the gut‑liver‑kidney axis as an integrated systems biology framework for understanding CKD progression and to translate this framework into diagnostic, therapeutic and clinical trial strategies. The present review aimed to combine mechanistic summaries with systems biology perspectives, including weighted gene co‑expression network analysis, Bayesian causal inference and ordinary differential equation‑based dynamic modeling, to map bidirectional signaling across microbial, metabolic, inflammatory and hemodynamic dimensions, with diabetic kidney disease (DKD) as the principal exemplar. The axis operates through anatomically and molecularly defined positive feedback loops in which gut dysbiosis drives barrier failure and endotoxemia, amplifying hepatic lipotoxicity and bile acid dysregulation, precipitating renal tubular injury and fibrosis. This self‑perpetuating cycle, sustained by uremic toxin signaling, dysregulated peroxisome proliferator‑activated receptor/farnesoid X receptor (FXR)/Takeda G protein‑coupled receptor 5 (TGR5) pathways and trained immunity (a persistent hyperinflammatory state of innate immune cells driven by epigenetic and metabolic reprogramming), is most pronounced in DKD. Microbiome‑targeted interventions and FXR/TGR5 modulators are as the most clinically advanced axis‑directed strategies, though most remain at preclinical or early‑phase stages. Reframing CKD as gut‑liver‑kidney axis dysfunction enables systems‑level mechanistic integration, precision diagnostics through composite microbiome‑metabolomic signatures, and adaptive trial designs targeting upstream pathology, providing a foundation for incorporating axis‑based approaches into future CKD management.
科研通智能强力驱动
Strongly Powered by AbleSci AI